Procalcitonin-guided antibiotic therapy for pediatrics with infective disease: A updated meta-analyses and trial...

Area of Science:

• Pediatric Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Antibiotic overuse contributes to antimicrobial resistance and adverse events.
• Biomarkers like procalcitonin (PCT) can guide antibiotic stewardship.
• Pediatric infectious diseases require careful management to balance efficacy and safety.

Purpose of the Study:

• To evaluate the impact of procalcitonin (PCT)-guided therapy on antibiotic exposure in pediatric patients with infectious diseases.
• To synthesize evidence from randomized controlled trials (RCTs) on PCT-guided antibiotic management.
• To assess the effect of PCT guidance on antibiotic duration, adverse events, and clinical outcomes.

Main Methods:

• An updated systematic review and meta-analysis of four RCTs involving 1,313 pediatric patients.
• Searches conducted across major databases including MEDLINE, Embase, and Cochrane.
• Trial sequential analysis (TSA) used to calculate required information size (RIS) and assess the robustness of findings.

Main Results:

• PCT-guided antibiotic therapy was associated with a significantly shorter duration of antibiotic treatment (-2.22 days) compared to standard care.
• A decreased rate of antibiotic-related adverse events was observed in the PCT-guided group (RR, 0.25).
• No significant differences were found in hospital stay, antibiotic prescription rates, readmission, or mortality.

Conclusions:

• Procalcitonin (PCT)-guided management effectively reduces antibiotic exposure in pediatric infectious diseases.
• The findings suggest a potential benefit in decreasing antibiotic duration and associated adverse events.
• Larger prospective clinical studies are necessary to confirm these results and further elucidate the role of PCT in pediatric infectious disease management.